Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178123 | 1.00 | SLC6A2 (0.39) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL5068915 | 0.80 | NR1H2 (0.52) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL23557563 | 0.79 | ESR1 (0.41) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL17886084 | 0.79 | ESR1 (0.41) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL14977000 | 0.77 | CSNK1E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL2003776 | 0.76 | ADRB2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2A6LMNA | |
| SCHEMBL2007621 | 0.76 | NR1H2 (0.40) | MAOA | |
| SCHEMBL7743398 | 0.75 | MAOA (0.35) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL28591973 | 0.75 | TAAR1 (0.40) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL19309372 | 0.73 | ESR1 (0.41) | TAAR1ADRA2AADRA2CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782920-B1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | claimed |
| US-20140315858-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | claimed |
| EP-2782920-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2014-10-01 | — | — | EP | claimed |
| WO-2013075817-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-30 | — | — | WO | claimed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | claimed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | claimed |
| US-9617286-B2 | Fungicide N-[(trisubstitutedsilyl)methyl]-carboxamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2782920-B1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20140315858-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2782920-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013075817-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007073560-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | RND PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315858-A1 | FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES | TET3, TET1, PFAS | SLC6A2 3457/4885TAAR1 3044/4885MAOA 1898/4885 |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | PTGES2, PTGS2, SI | SLC6A2 426/4885TAAR1 2888/4885MAOA 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.